WallStSmart

DarioHealth Corp (DRIO)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 316925% more annual revenue ($66.57B vs $21.00M). MRK leads profitability with a 4.8% profit margin vs -169.9%. MRK earns a higher WallStSmart Score of 36/100 (F).

DRIO

Avoid

23

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 5.3Quality: 5.0
Piotroski: 3/9Altman Z: -5.45

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DRIOUndervalued (+7.4%)

Margin of Safety

+7.4%

Fair Value

$11.88

Current Price

$6.63

$5.25 discount

UndervaluedFair: $11.88Overvalued
MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.81

$65.77 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DRIO2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Return on EquityProfitability
100.5%10/10

Every $100 of equity generates 101 in profit

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

DRIO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$67.91M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-3.6%2/10

Revenue declined 3.6%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : DRIO

The strongest argument for DRIO centers on Price/Book, Return on Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : DRIO

The primary concerns for DRIO are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

DRIO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

DRIO carries more volatility with a beta of 1.12 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DarioHealth Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

DarioHealth Corp. The company is headquartered in New York, New York.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?